Pharmaceuticals Phase 3 Data Demonstrate Efficacy of Lenacapavir for HIV Prevention in Cisgender Women Last updated: July 24, 2024 3:50 pm By bexib 0 Min Read Share SHARE Results from the PURPOSE 1 trial showed that treatment with lenacapavir was superior to treatment with Descovy and Truvada. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article Bitcoin is the cash of the internet Next Article Remy Cointreau is too focused on Cognac, say investors Reuters – Investorempires.com Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News A look inside: Allies developing a multicloud hybrid strategy Banking 2024 Holiday Shipping Deadline for the United States International Shipping Ecommerce taxes – How to stay ahead of the sales tax maze Retail & E-commerce Finastra breach: 3 security points Banking